Direct Endoscopic Jejunostomy for the Administration of Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease

被引：0
|
作者：
Vinh-an Phan [1 ]
Schoeman, Mark [1 ]
Kimber, Thomas [2 ]
机构：
[1] Royal Adelaide Hosp, Gastroenterol & Hepatol, Adelaide, SA, Australia
[2] Royal Adelaide Hosp, Dept Neurol, Adelaide, SA, Australia
来源：
GASTROINTESTINAL ENDOSCOPY | 2015年 / 81卷 / 05期
关键词：
D O I：
10.1016/j.gie.2015.03.464
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1503
引用
收藏
页码：AB307 / AB308
页数：6
相关论文
共 50 条
  • [21] Weight, BMI, and Dyskinesia in Patients With Parkinson's Disease on Levodopa-Carbidopa Intestinal Gel
    Pontieri, F.
    Bourgeois, P.
    Chaudhuri, K.
    Siddiqui, M.
    Bergmann, L.
    Kukreja, P.
    Ladhani, O.
    Simu, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 230 - 230
  • [22] Efficacy of Levodopa-Carbidopa Intestinal Gel Versus Oral Levodopa-Carbidopa in Advanced Parkinson's: Sensitivity and Responder Analyses
    Boyd, James T.
    Fernandez, Hubert H.
    Slevin, John T.
    Espay, Alberto J.
    Standaert, David G.
    Pritchett, Yili
    Zhang, Wuyan
    Chatamra, Krai
    Widnell, Katherine L.
    Benesh, Janet
    ANNALS OF NEUROLOGY, 2013, 74 : S44 - S44
  • [23] Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease
    van Laar, T.
    Nyholm, D.
    Nyman, R.
    ACTA NEUROLOGICA SCANDINAVICA, 2016, 133 (03): : 208 - 215
  • [24] Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations
    R. Balestrino
    T. Martone
    M. Toffoli
    E. Montanaro
    M. Fabbri
    C. A. Artusi
    A. Romagnolo
    M. Zibetti
    M. Rizzone
    S. Goldwurm
    L. Lopiano
    A. H. V. Schapira
    Neurological Sciences, 2024, 45 : 1489 - 1497
  • [25] The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England
    K. Ray Chaudhuri
    A. Simon Pickard
    Ali Alobaidi
    Yash J. Jalundhwala
    Prasanna L. Kandukuri
    Yanjun Bao
    Julia Sus
    Glynn Jones
    Christian Ridley
    Julia Oddsdottir
    Seyavash Najle-Rahim
    Matthew Madin-Warburton
    Weiwei Xu
    Anette Schrag
    PharmacoEconomics, 2022, 40 : 559 - 574
  • [26] Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel Versus Oral Administration of Levodopa-Carbidopa Tablets in Japanese Subjects with Advanced Parkinson's Disease: Pharmacokinetics and Pilot Efficacy and Safety
    Othman, Ahmed A.
    Chatamra, Krai
    Mohamed, Mohamed-Eslam F.
    Dutta, Sandeep
    Benesh, Janet
    Yanagawa, Masayoshi
    Nagai, Masahiro
    CLINICAL PHARMACOKINETICS, 2015, 54 (09) : 975 - 984
  • [27] Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations
    Balestrino, R.
    Martone, T.
    Toffoli, M.
    Montanaro, E.
    Fabbri, M.
    Artusi, C. A.
    Romagnolo, A.
    Zibetti, M.
    Rizzone, M.
    Goldwurm, S.
    Lopiano, L.
    Schapira, A. H. V.
    NEUROLOGICAL SCIENCES, 2024, 45 (04) : 1489 - 1497
  • [28] Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson's disease patients
    Karadag, Yesim Sucullu
    Saltoglu, Tugce
    Kucukdagli, Fadime Erdogan
    Ozturk, Omer
    Koseoglu, Tankut
    Altiparmak, Emin
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2021, 51 (01) : 84 - 89
  • [29] Does levodopa-carbidopa intestinal gel in Parkinson's disease patients increase the risk on polyneuropathy?
    Moes, H.
    Drent, M.
    Laar, T.
    MOVEMENT DISORDERS, 2017, 32
  • [30] Levodopa-carbidopa intestinal gel is an option in Parkinson’s disease with hyponatremia induced by dopamine agonists
    Marina Picillo
    Vincenzo Canoro
    Giulio Cicarelli
    Roberto Erro
    Paolo Barone
    Neurological Sciences, 2020, 41 : 3361 - 3363
12345